Topoisomerase‐1 and ‐2A gene copy numbers are elevated in mismatch repair‐proficient colorectal cancers

Molecular Oncology - Tập 9 - Trang 1207-1217 - 2015
Ida Marie Heeholm Sønderstrup1, Sune Boris Nygård2, Tim Svenstrup Poulsen1, Dorte Linnemann1, Jan Stenvang2, Hans Jørgen Nielsen3, Jiri Bartek4,5, Nils Brünner2, Peter Nørgaard1, Lene Riis1
1Department of Pathology, Herlev Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark
2Section of Molecular Disease Biology, Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, Grønnegårdsvej 15, DK-1870 Frederiksberg C, Denmark
3Department of Surgical Gastroenterology, Copenhagen University Hospital, Hvidovre, Kettegårds Allé 30, DK-2650 Hvidovre, Denmark
4Danish Cancer Research Center, The Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen Ø, Denmark
5Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Tr Svobody 8, 771 26 Olomouc, Czech Republic

Tóm tắt

Introduction Topoisomerase 1 (TOP1) and 2A (TOP2A) are potential predictive biomarkers for irinotecan and anthracycline treatment, respectively, in colorectal cancer (CRC), and we have recently reported a high frequency of gene gain of the TOP1 and TOP2A genes in CRC. Furthermore, Mismatch Repair (MMR) subtypes of CRC have been associated with benefit from adjuvant chemotherapy of primary CRC. Given the involvement of the topoisomerase enzymes in DNA replication and repair, we raised the hypothesis that an association may exist between TOP gene copy numbers and MMR proficiency/deficiency in CRC.Material and methods Test cohort: FISH analysis with an in‐house TOP1/CEN20 probe mix and a commercially available TOP2A/CEN17 (Dako, Glostrup, Denmark) probe mix was performed on archival formalin fixed paraffin embedded (FFPE) tissue samples from 18 patients with proficient MMR (pMMR) CRC and 18 patients with deficient MMR (dMMR) CRC. TOP1 and TOP2A gene copy numbers and their ratios per nucleus were correlated with MMR status using the Mann–Whitney test. Validation cohort: FFPE samples from 154 patients with primary stage III CRC (originally included in the RANX05 study) were classified according to MMR status by immunohistochemical analysis using validated antibodies for MLH1, MLH2, MSH6 and PMS2, and information on TOP1, CEN20, TOP2A and CEN17 status was previously published for this cohort.ResultsThe observed TOP1 gene copy numbers in the 36 CRC test cohort were significantly greater (p < 0.01) in the pMMR subgroup (mean: 3.84, SD: 2.03) than in the dMMR subgroup (mean: 1.50, SD: 0.12). Similarly, the TOP2A copy numbers were significantly greater (p < 0.01) in the pMMR subgroup (mean: 1.99, SD: 0.52) than in the dMMR subgroup (mean: 1.52, SD: 0.10). These findings were confirmed in the validation cohort, where in the pMMR subgroup 51% had ≥2 extra TOP1 copies per cell, while all tumors classified as dMMR had diploid TOP1 status and mean TOP2A copy numbers were 2.30 (SD: 1.36) and 1.80 (SD: 0.31) (p = 0.01) in the pMMR subgroup vs. dMMR subgroup, respectively.Discussion and conclusionOur results show that TOP1 and TOP2A gene copy numbers are increased in the pMMR subgroup. We propose that this preference may reflect a selective pressure to gain and/or maintain the gained extra copies of topoisomerase genes whose products are required to cope with high replication stress present in the pMMR tumors, thereby providing a survival advantage selectively in pMMR tumors. Future studies should test this concept and explore potential differences between pMMR and dMMR tumors in response to Top1 and Top2 inhibitors.

Tài liệu tham khảo

10.1038/nsmb.2220 10.1038/nature03482 10.1016/j.molcel.2012.03.001 10.1053/hupa.2002.129202 10.1016/S0165-4608(00)00242-9 10.1200/JCO.2007.15.5580 10.1038/nature11935 10.1078/0065-1281-00590 Des Guetz G., 2009, Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis, Anticancer Res., 29, 1615 10.1016/S1470-2045(11)70231-5 10.1007/s10549-011-1694-9 10.5858/arpa.2011-0035-RA 10.1053/j.gastro.2008.07.076 10.1016/j.ejca.2010.05.009 10.1126/science.1140735 10.1016/S1359-6349(09)71098-5 10.1186/1471-2407-9-339 10.1007/s00109-006-0126-5 10.1038/386623a0 Michaelson R., 1982, Phase II evaluation of 4'-epi-doxorubicin in patients with advanced colorectal carcinoma, Cancer Treat Rep., 66, 1757 10.1038/sj.bjc.6603361 2014 National Comprehensive Cancer Network NCCN Guidelines Version 3 Nielsen H.J., 1998, The effect of ranitidine on long-term survival in primary colorectal cancer. A 40 months interim analysis, GI Cancer, 227 10.1016/j.molonc.2011.11.006 10.3109/00365521.2013.856464 10.3109/00365521.2013.848230 10.1080/02841860310019007 10.1002/ijc.20208 10.1016/j.tibs.2012.03.001 10.1016/j.chembiol.2010.04.012 Poulsen T.S., 2007, Purification of BAC DNA. Bacterial Artificial Chromosomes Volume 1: Library Construction, Physical Mapping, and Sequencing, 91 Poulsen T.S., 2007, BAC End Sequencing. Bacterial Artificial Chromosomes Volume 1: Library Construction, Physical Mapping, and Sequencing, 157 10.1016/j.molonc.2012.09.001 10.1371/journal.pone.0060613 Staley B.E., 1999, Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon, Mod. Pathol., 12, 356 10.1007/s00280-008-0886-4 10.1038/nrm831 10.1007/BF00171592 10.1016/0046-8177(94)90223-2
Thông tin
Thông tin xuất bản

Molecular Oncology

Tập 9

1207-1217

Thông tin tác giả